Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,312 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

Folic Acid Supplementation in Pregnant Women: Dose Response

NCT02124642
Conditions
Pregnancy
Interventions
Folic acid, 400 mcg/day, Folic acid 800 mcg/day
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Athens, Georgia
Conditions
Breast Cancer
Interventions
biologic sample preservation procedure, laboratory biomarker analysis, biopsy
Other · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed No phase listed Observational Results available

Utility of Novel BRAF Test for Melanoma

NCT01840527
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema, Headache, Visual Impairment
Interventions
Non-interventional study
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
San Diego, California • Newark, Delaware • Boca Raton, Florida + 19 more
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Conditions
Glioblastoma Multiforme
Interventions
Not listed
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2018 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Pre-term Birth
Interventions
Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg, Standard of Care
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Leigh Syndrome
Interventions
None (Observational study)
Other
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Terminated Not applicable Interventional Accepts healthy volunteers

Investigating Biological Markers, Targets, and Intervention for Mood Disorders

NCT04632498
Conditions
Major Depressive Disorder, Depression, Stress
Interventions
Mindfulness Based Intervention
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Urinary Biomarkers of OI Pathobiology

NCT02531087
Conditions
Osteogenesis Imperfecta
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Omaha, Nebraska • New York, New York + 3 more
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Cystic Fibrosis, Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Pulmonary Nodule
Interventions
Blood collection, Chest Computed Tomography
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Nashville, Tennessee
Conditions
Liver Cancer
Interventions
Lipiodol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Conditions
Head and Neck Cancer
Interventions
fruit and vegetable extracts, placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
28
States / cities
Santa Rosa, California • Newark, Delaware • Washington D.C., District of Columbia + 23 more
Conditions
Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Basal Cell Carcinoma of Skin, Site Unspecified, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
Interventions
Blood draw for the laboratory assessment
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Terminated No phase listed Observational Accepts healthy volunteers

Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel

NCT01957501
Conditions
Major Depressive Disorder, Bipolar Disorder, Serum Biomarkers
Interventions
MDDScoreTM
Other
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 21 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational

SPINCOMS Biomarker Study

NCT04496830
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting Phase 2 Interventional Accepts healthy volunteers

DORA and LP in Alzheimer's Disease Biomarkers

NCT06274528
Conditions
Alzheimer Disease
Interventions
Lemborexant 10 mg, Lemborexant 20mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Obstructive Sleep Apnea of Child
Interventions
Cytokine from blood
Diagnostic Test
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 10 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Tumor, Primary, Brain Metastases, Adult
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Schizophrenia, Psychosis, Serious Mental Illness, PTSD, Schizoaffective Disorder, Bipolar Disorder
Interventions
Targeted Cognitive Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 83 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California